Last reviewed · How we verify
NCT05832164: HIDRA360
Effectiveness of a Multifactorial Intervention in Frailty Individuals With HIV Infection: HIDRA360
NA trial testing Multifactorial intervention in Frailty Syndrome in 61 participants. Status unknown.
31 October 2023
Quick facts
| Lead sponsor | Hospital Costa del Sol |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 61 |
| Start date | 15 December 2022 |
| Primary completion | 31 October 2023 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Multifactorial intervention
Conditions studied
- Frailty Syndrome — all drugs for Frailty Syndrome →
- HIV Infections — all drugs for HIV Infections →
Sponsor
Hospital Costa del Sol
Who can join
60 and older, any sex, with Frailty Syndrome or HIV Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this quasi-experimental before/after study without equivalent control group is to to describe the prevalence of frail, pre-fragile and robust individuals in the study group before and after a multifactorial intervention in in frail HIV patients. The main questions it aims to answer are after a multifactorial intervention: 1. To describe the sociodemographic, viroimmunological and ART exposure factors of fragile individuals compared to pre-fragile and robust individuals. 2. To describe adherence to the Mediterranean diet in frail individuals compared to pre-frail and robust individuals. 3. To describe the presence of anxiety and depression in frail individuals with respect to pre-fragile and robust individuals. 4. To describe the analytical parameters and inflammatory markers of frail individuals with respect to pre-fragile and robust individuals. 5. To describe the diversity and composition of the intestinal microbiota of frail individuals with respect to pre-fragile and robust individuals. 6. To describe the body composition of frail individuals with respect to pre-fragile and robust individuals. 7. To describe the factors associated with progression to frailty or robustness after six months of a multifactorial intervention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05832164
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Multifactorial intervention
Trials testing the same drug.
- NCT04942119 — Impact of Long-term Serum Magnesium and Potassium Levels Optimization and Multifactorial Adherence Intervention on the P · NA · unknown
- NCT04276012 — Effectiveness of a Cardiovascular Risk Intervention Program in Patients With Schizophrenia (PRISCA) · NA · unknown
Other recruiting trials for Frailty Syndrome
Currently open trials in the same condition.
- NCT07465159 — Multimodal Prehabilitation of Frail Patients Undergoing Elective Knee or Hip Replacement · NA · recruiting
- NCT07258615 — Longitudinal Ultrasound Assessment of Diaphragmatic and Respiratory Muscle Function Following Respiratory Muscle Trainin · NA · active not recruiting
- NCT07348081 — Real World Evidence to Assess the Value of a Digital Care Coordination and Monitoring Program for Supporting Caregivers · NA · recruiting
- NCT07338929 — Physical Performance Assessment in Kidney Transplant Evaluation · recruiting
- NCT07071142 — Frailty and Outcomes in Older Heart Failure Patients With Ejection Fraction >40% · active not recruiting
Other Hospital Costa del Sol trials
Trials by the same sponsor.
- NCT07169539 — Digital Tool for Psychological Support in Women With Breast Cancer · NA · not yet recruiting
- NCT06019585 — Inmobilization With Compression Bandage vs Antebraquial Splint in Distal Radius Fractures · NA · recruiting
- NCT05600218 — RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05832164 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Costa del Sol
- Last refreshed: 6 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05832164.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing